---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Care management intervention strategies"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Care management intervention strategies. Topics: Immunoglobulin dose optimization and cessation trials; Subcutaneous immunoglobulin dose reduction; Home and subcutaneous administration; Outcome monitoring with disability, strength, and patient-reported scales; 1 further topic. 5 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Immunoglobulin dose optimization and cessation trials

> “Periodic IVIG optimization trials using objective outcomes are encouraged in all CIDP patients receiving chronic IVIG treatment as a means to identify the lowest effective IVIG dose and frequency.”
> “In both groups, drug‐free remission was achieved in about one‐third of patients.”

Source: [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)

> “The successful cessation trials resulted in a cost saving of £855 000/year, with a potential further saving of £1.7 million/year if all the eligible individuals had consented.”
> “All patients who deteriorated were rescued to previous baseline on retreatment.”
> “Individuals with CIDP should be counselled about the natural history of the disease and future scheduled, targeted cessation trials. A dedicated clinical infrastructure is vital to safely perform cessation trials.”

Source: [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)

> “Not all patients may require continued maintenance therapy beyond the initial 6 months of therapy in order to maintain their therapeutic response.”

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

<a id="topic-2.2.2.4-2"></a>

### Subcutaneous immunoglobulin dose reduction

> “After dose reduction from 0.4 to 0.2 g/kg, 51% (27/53) of patients relapsed, of whom 92% (24 of 26) improved after reinitiation of the 0.4 g/kg dose.”
> “Two-thirds of patients (19/28) who completed the PATH study without relapse remained relapse-free on the 0.2 g/kg dose after dose reduction in the extension study.”
> “Long-term dosing should be individualized to find the most appropriate dose in a given patient.”

Source: [van Schaik et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6624149/)

> “If CIDP symptoms worsen, on 0.2 g/kg (1 mL/kg) body weight per week, consider increasing the HIZENTRA dose from 0.2 g/kg to 0.4 g/kg body weight per week.”
> “Monitor patient’s clinical response and adjust duration of therapy based on patient need.”

Source: [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)

<a id="topic-2.2.2.4-3"></a>

### Home and subcutaneous administration

> “Eight consecutive patients, four with MMN and four with CIDP, already on long-term, hospital-based IVIG were switched to home-based SCIG.”
> “In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.”

Source: [Hadden et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4286942/)

> “The most important factors in treatment decision-making were a lower chance of CIDP symptom worsening in 6 months, less frequent treatment administration, and home infusion (all p < 0.001 vs reference categories).”

Source: [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

> “In addition, like conventional SCIG, fSCIG 10% offers the potential convenience of home administration, 13 leading to possible cost savings and eliminating burden of travel to an infusion center or other facility over multiple days.”

Source: [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)

> “Home infusions are generally safe, effective, convenient, and less costly than infusions in other sites of care (eg, physician office, outpatient hospital), making this a frequently used site of care for infusions, either by choice or through health plan benefit design.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

<a id="topic-2.2.2.4-4"></a>

### Outcome monitoring with disability, strength, and patient-reported scales

> “Assessing strength impairment, disability, and quality of life is ideally suited for everyday practice when caring for patients with CIDP.”
> “Such data are critically important when justifying the need for ongoing or periodic immunotherapy, documenting relapse or deterioration, or providing reassurance of disease improvement, stability, or remission.”

Source: [Allen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32338716/)

> “Frequent assessment of grip strength can be a useful tool to identify intravenous immunoglobulin (IVIG) treatment‐related fluctuations (TRFs) and optimize IVIG treatment in real‐time, but the long‐term implications of TRFs are unknown.”

Source: [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)

> “The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (≥1 points aINCAT decrease, ≥4 points [centile metric] Inflammatory Rasch-built Overall Disability Scale increase, or ≥8 kPa grip strength increase after four injections and two consecutive visits).”

Source: [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)

<a id="topic-2.2.2.4-5"></a>

### Remote monitoring of grip strength and patient-reported outcomes

> “Patients were monitored weekly or monthly, based on stability and patient preference, using grip strength, modified timed‐up‐and go (mTUG), and patient‐reported outcome measures (PROMs).”
> “Adherence was 93% (95% CI: 91.9%–94.1%).”
> “Grip strength and mTUG ICCs were both 0.96 (95% CI: 0.93–0.98 and 0.92–0.99, respectively).”

Source: [Lemmen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11915482/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
